Browse by author
Lookup NU author(s): Dr Ian HardcastleORCiD
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0).
The study of cellular mechanisms of cancer growth and survival has revealed a complex web of signalling pathways that produce the ‘hallmarks of cancer’. A number of critical cellular signalling nodes have been characterised from which many new drug targets have been proposed. A number of these nodes are regulated by protein-protein interactions, and so present attractive, if challenging, targets for drug discovery. Drug discovery efforts towards three PPI families have resulted in clinically investigated drugs: i.e. Bcl-2 family inhibitors, MDM2-p53 inhibitors and IAP inhibitors. The discovery and optimisation of these drug classes are detailed in this chapter.
Author(s): Hardcastle IR
Editor(s): Bernstein, PR; Georg, GI; Keller, Th; Kobayashi, T; Lowe, JA; Meanwell, NA; Saxena, AK; Stilz, U; Supuran, CT; Zhang, A
Publication type: Book Chapter
Publication status: Published
Book Title: Topics in Medicinal Chemistry
Year: 2017
Pages: 1-35
Online publication date: 25/07/2017
Acceptance date: 30/06/2017
Publisher: Springer
Place Published: Berlin, Heidelberg
URL: https://doi.org/10.1007/7355_2017_27
DOI: 10.1007/7355_2017_27
